Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ZW220
i
Other names:
ZW220
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Zymeworks
Drug class:
Topoisomerase I inhibitor, NaPi2b-targeted antibody-drug conjugate
Related drugs:
‹
fam-trastuzumab deruxtecan-nxki (61)
irinotecan (48)
U3-1402 (24)
topotecan (16)
sacituzumab govitecan-hziy (14)
DS-1062a (5)
DS-7300 (5)
AMB302 (4)
AZD8205 (4)
DB-1310 (3)
DS-6157 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
SSH20 (2)
AZD9592 (1)
BAT8008 (1)
camptothecin nanosomal (1)
DB-1303 (1)
ELU001 (1)
IT-141 (1)
MK-2870 (1)
STRO-003 (1)
IMMU-130 (1)
XMT-1592 (2)
XMT-1536 (2)
fam-trastuzumab deruxtecan-nxki (61)
irinotecan (48)
U3-1402 (24)
topotecan (16)
sacituzumab govitecan-hziy (14)
DS-1062a (5)
DS-7300 (5)
AMB302 (4)
AZD8205 (4)
DB-1310 (3)
DS-6157 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
SSH20 (2)
AZD9592 (1)
BAT8008 (1)
camptothecin nanosomal (1)
DB-1303 (1)
ELU001 (1)
IT-141 (1)
MK-2870 (1)
STRO-003 (1)
IMMU-130 (1)
XMT-1592 (2)
XMT-1536 (2)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
SLC34A2 expression
Ovarian Cancer
SLC34A2 expression
Ovarian Cancer
ZW220
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ZW220
Sensitive
:
D
AACR 2023 - 1wk
ZW220
Sensitive: D – Preclinical
AACR 2023 - 1 week
ZW220
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login